Methyldopa

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Methyldopa
   1. Pharmacist Assessment Report
   2. Methyldopa: Known uses and market status in Australia
   3. Summary
   4. Quick overview
   5. Known uses recorded for this drug
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Australia Market Information
   7. Safety Considerations
   8. Disclaimer

---

Pharmacist Assessment Report

Methyldopa: Known uses and market status in Australia

Summary

The TxGNN model (deep learning) has no candidate with a score of 0.99 or higher for Methyldopa, so there is currently no new predicted indication. The drug’s recorded uses are listed below.

Quick overview

Item	Content
New predicted indications	None (no model candidate scored 0.99 or higher)
Known uses recorded for this drug	2
Evidence level	Not applicable
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)

Known uses recorded for this drug

Approved (supported by a licence or label)

Indication	Source
none	none

Related to an approved indication (same disease category)

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
hypertension
hypertensive disorder

Australia Market Information

Licence	Product	Dosage form	Status
1629R	Hydopa	Tablet 250 mg (as sesquihydrate)	Valid

Safety Considerations

Product label warnings and contraindications were not available in the data compiled for this report. Please refer to the TGA-approved Product Information (PI) for authoritative safety information.

Contraindications suggested by the knowledge graph (not label text): the TxGNN knowledge graph links methyldopa with the following conditions, which should be verified against the PI:

• Liver disease: liver failure, cirrhosis, hepatic coma and encephalopathy
• Kidney disease and anuria
• Congestive heart failure
• Autoimmune conditions: systemic lupus erythematosus, autoimmune haemolytic anaemia
• Porphyria
• Diabetes mellitus and diabetic ketoacidosis
• Pancreatitis and gallbladder disease
• Gout, hyperparathyroidism and hypercalcaemia
• Anxiety, neurotic and dysthymic disorders
• Potassium deficiency and neonatal jaundice

Drug Interactions: 100 interactions are recorded (the 20 listed in the data are mostly Moderate, with a few Minor). Main ones include:

• Moderate: corticosteroids (hydrocortisone, prednisolone, prednisone, dexamethasone, betamethasone, triamcinolone, budesonide), epinephrine, ephedrine, SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin), iron, naltrexone, dronabinol and nabilone
• Minor: sulfonylureas (chlorpropamide, glimepiride, tolazamide)

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---